MX2021001765A - Tratamiento del linfoma follicular reicindido. - Google Patents

Tratamiento del linfoma follicular reicindido.

Info

Publication number
MX2021001765A
MX2021001765A MX2021001765A MX2021001765A MX2021001765A MX 2021001765 A MX2021001765 A MX 2021001765A MX 2021001765 A MX2021001765 A MX 2021001765A MX 2021001765 A MX2021001765 A MX 2021001765A MX 2021001765 A MX2021001765 A MX 2021001765A
Authority
MX
Mexico
Prior art keywords
follicular lymphoma
treatment
relapsed follicular
immunochemotherapy
phosphoinositide
Prior art date
Application number
MX2021001765A
Other languages
English (en)
Spanish (es)
Inventor
Daniel P Gold
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of MX2021001765A publication Critical patent/MX2021001765A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021001765A 2018-08-14 2019-08-13 Tratamiento del linfoma follicular reicindido. MX2021001765A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862718926P 2018-08-14 2018-08-14
US201962836507P 2019-04-19 2019-04-19
PCT/US2019/046408 WO2020036997A1 (en) 2018-08-14 2019-08-13 Treatment of relapsed follicular lymphoma

Publications (1)

Publication Number Publication Date
MX2021001765A true MX2021001765A (es) 2021-04-19

Family

ID=69525835

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001765A MX2021001765A (es) 2018-08-14 2019-08-13 Tratamiento del linfoma follicular reicindido.

Country Status (14)

Country Link
US (1) US20210196725A1 (https=)
EP (1) EP3836936A4 (https=)
JP (1) JP2021534116A (https=)
KR (1) KR20210043637A (https=)
CN (1) CN112839659A (https=)
AU (1) AU2019321526A1 (https=)
BR (1) BR112021002734A2 (https=)
CA (1) CA3109377A1 (https=)
IL (1) IL280721A (https=)
MA (1) MA53237A (https=)
MX (1) MX2021001765A (https=)
SG (1) SG11202101417XA (https=)
TW (1) TW202021593A (https=)
WO (1) WO2020036997A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2608967T3 (es) 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
US11304953B2 (en) 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
KR20200041358A (ko) 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919869B1 (fr) * 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
ES2608967T3 (es) * 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
BR112015002285B1 (pt) * 2012-08-09 2022-05-10 Celgene Corporation Uso do composto 3-(4-((4-(morfolinometil)benzil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona para tratar ou gerenciar câncer
MA38462A1 (fr) * 2013-04-08 2017-10-31 Bayer Pharma AG Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement de lymphomes
PT3262071T (pt) * 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
CN109982687A (zh) * 2016-09-19 2019-07-05 梅制药公司 联合疗法
KR20200041358A (ko) * 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법

Also Published As

Publication number Publication date
US20210196725A1 (en) 2021-07-01
JP2021534116A (ja) 2021-12-09
EP3836936A1 (en) 2021-06-23
EP3836936A4 (en) 2022-05-18
WO2020036997A1 (en) 2020-02-20
MA53237A (fr) 2021-06-23
CA3109377A1 (en) 2020-02-20
IL280721A (en) 2021-03-25
SG11202101417XA (en) 2021-03-30
TW202021593A (zh) 2020-06-16
AU2019321526A1 (en) 2021-03-25
BR112021002734A2 (pt) 2021-07-20
KR20210043637A (ko) 2021-04-21
CN112839659A (zh) 2021-05-25

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
MY209360A (en) Anti-cd47 and anti-cd20 based treatment of blood cancer
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
MY196582A (en) PD-1/PD-L1 Inhibitors
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
AU2018278311A1 (en) IRE1 small molecule inhibitors
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
WO2019090347A8 (en) Adenosine pathway inhibitors for cancer treatment
MX2020009773A (es) Terapia de combinacion.
EP4585273A3 (en) Mechanism of resistance to bet bromodomain inhibitors
MX2021001765A (es) Tratamiento del linfoma follicular reicindido.
MX390121B (es) Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas.
MX2018014577A (es) Combinacion de anticuerpo anti-cd20, inhibidor selectivo de quinasa p13-delta, e inhibidor de btk para tratar trastornos proliferativos de celulas b.
WO2019175260A3 (en) Modified oligonucleotides for use in treatment of tauopathies
MX2020011817A (es) Metodos para tratar el linfoma.
MX2019013862A (es) Terapia de combinacion.
MX2018001369A (es) Combinaciones de inhibidores de tirosina quinasa de bruton y sus usos.
MX2020001727A (es) Terapia de combinacion.
AU2017277478A1 (en) Pharmaceutical combinations for treating cancer
MX2023002104A (es) Composiciones y métodos para tratar cánceres positivos para egfr.
EA201992400A1 (ru) Композиции для ухода за волосами
PH12022551371A1 (en) Macrocycles for use in treating disease
MX2021004396A (es) Metodos y composiciones para el tratamiento de la mucositis oral.
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
WO2019204332A3 (en) Pak4 inhibitors and methods of use